FiercePharma3h
Otsuka calculates dementia caregivers would earn 6 figures if paid for work
Otsuka has quantified the financial impact of caregivers, calculating that people in the U.S. who look after loved ones with ...
FiercePharma19h
Vanda, despite FDA rejection, swats down another buyout bid from Cycle
The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s ...
FiercePharma22h
On road to crowded Crohn's disease market, Lilly's Omvoh bests J&J's Stelara in head-to-head study
On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...
FiercePharma23h
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
FiercePharma19h
Leqembi's vial design could result in hundreds of millions in annual Medicare waste: study
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
FiercePharma23h
Incyte picks Dr. Pimple Popper to expand Opzelura atopic dermatitis campaign
A year after kicking off a star-studded campaign to highlight the stories of real patients with atopic dermatitis, Incyte has ...